|
1
|
Doroshow DB, Sanmamed MF, Hastings K,
Politi K, Rimm DL, Chen L, Melero I, Schalper KA and Herbst RS:
Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin
Cancer Res. 25:4592–4602. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boutros C, Tarhini A, Routier E, Lambotte
O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S,
Berdelou A, et al: Safety profiles of anti-CTLA-4 and anti-PD-1
antibodies alone and in combination. Nat Rev Clin Oncol.
13:473–486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reckamp KL, Redman MW, Dragnev KH,
Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S,
Everhart L, Highleyman L, et al: Phase II randomized study of
ramucirumab and pembrolizumab versus standard of care in advanced
non-small-cell lung cancer previously treated with
immunotherapy-lung-MAP S1800A. J Clin Oncol. 40:2295–2306. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing P, Wang M, Zhao J, Zhong W, Chi Y, Xu
Z and Li J: Study protocol: A single-arm, multicenter, phase II
trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC
previously treated with first-line immunotherapy. Thorac Cancer.
12:2825–2828. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hammers CM and Stanley JR: Mechanisms of
disease: Pemphigus and bullous pemphigoid. Annu Rev Pathol.
11:175–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaul S, Wang A, Grushchak S and Albrecht
J: Pembrolizumab-induced reactivation of bullous pemphigoid. Int J
Dermatol. 60:757–758. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tison A, Quéré G, Misery L, Funck-Brentano
E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud
B, et al: Safety and efficacy of immune checkpoint inhibitors in
patients with cancer and preexisting autoimmune disease: A
nationwide, multicenter cohort study. Arthritis Rheumatol.
71:2100–2111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rami-Porta R, Asamura H, Travis WD and
Rusch VW: Lung cancer-major changes in the American joint committee
on cancer eighth edition cancer staging manual. CA Cancer J Clin.
67:138–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiers BH, Sahn RE and Callen JP:
Cutaneous manifestations of internal malignancy. CA Cancer J Clin.
59:73–98. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lucariello RJ, Villablanca SE, Mascaró JM
Jr and Reichel M: Association between bullous pemphigoid and
malignancy: A meta-analysis. Australas J Dermatol. 59:253–260.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Das A, Das S, Das SK and Basuthakur S: A
case of paraneoplastic bullous pemphigoid in association with
squamous cell carcinoma of lung. J Postgrad Med. 61:197–199. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Md Radzi AB and Kasim SS: A case report of
paraneoplastic bullous pemphigoid associated with mantle cell
lymphoma: A rare presentation. Medicine (Baltimore).
102:e328222023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Albadri Z, Thorslund K, Häbel H, Seifert O
and Grönhagen C: Increased risk of squamous cell carcinoma of the
skin and lymphoma among 5,739 patients with bullous pemphigoid: A
Swedish nationwide cohort study. Acta Derm Venereol.
100:adv002892020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balestri R, Magnano M, La Placa M, Patrizi
A, Angileri L, Tengattini V and Bardazzi F: Malignancies in bullous
pemphigoid: A controversial association. J Dermatol. 43:125–133.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moro F, Fania L, Sinagra JLM, Salemme A
and Di Zenzo G: Bullous pemphigoid: Trigger and predisposing
factors. Biomolecules. 10:14322020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant Nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leonardi GC, Gainor JF, Altan M, Kravets
S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann
MD and Awad MM: Safety of programmed death-1 pathway inhibitors
among patients with non-small-cell lung cancer and preexisting
autoimmune disorders. J Clin Oncol. 36:1905–1912. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dafni U, Tsourti Z, Vervita K and Peters
S: Immune checkpoint inhibitors, alone or in combination with
chemotherapy, as first-line treatment for advanced non-small cell
lung cancer. A systematic review and network meta-analysis. Lung
Cancer. 134:127–140. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu L, Bai H, Wang C, Seery S, Wang Z,
Duan J, Li S, Xue P, Wang G, Sun Y, et al: Efficacy and safety of
first-line immunotherapy combinations for advanced NSCLC: A
systematic review and network meta-analysis. J Thorac Oncol.
16:1099–1117. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomasini P, Barlesi F, Mascaux C and
Greillier L: Pemetrexed for advanced stage nonsquamous non-small
cell lung cancer: Latest evidence about its extended use and
outcomes. Ther Adv Med Oncol. 8:198–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arbour KC, Mezquita L, Long N, Rizvi H,
Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL,
et al: Impact of baseline steroids on efficacy of programmed cell
death-1 and programmed death-ligand 1 blockade in patients with
non-small-cell lung cancer. J Clin Oncol. 36:2872–2878. 2018.
View Article : Google Scholar : PubMed/NCBI
|
